Skip to main content
Signal8
Launch Terminal

EBR Systems, Inc. (EBRCZ)

EBR Systems, Inc. focuses on developing internal medical devices that utilize wireless technology for tissue stimulation. A key offering is their WiSE cardiac resynchronization therapy (CRT) system, which leverages proprietary cable-free technology to deliver electrical pacing directly into the heart's left ventricle. This innovative approach aims to address and eliminate the typical difficulties associated with traditional wired leads, such as challenging insertion, unintended nerve activation, device displacement, complex removal procedures, and the need for frequent repositioning. The company was established in 2003 and operates from its headquarters in Sunnyvale, California.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

EBR Systems, Inc. logo

EBR Systems, Inc.

OTC:EBRCZHealthcare
+2.57%$0.1177
Mkt Cap$88.63M
Float620.84M
O/S752.98M
Vol
$ Vol
RVOL
Inst Own-
SI<0.1%
Earnings
Dilution
EBR Systems, Inc. logoOTC:EBRCZ$0.1177+2.57%
Phase Distribution
6 lead-sponsored trials·4 active·2 completed
Not applicable6
(1 more as collaborator)
Status Overview
Recruiting2
Active, not recruiting2
Completed2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Not applicable
    Completed

    Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy

    Wireless cardiac stimulator implant to pace the left ventricle for CRT

    Heart Failure, Ventricular Dysfunction +1

    Enrollment
    17
    Start
    Feb 2011
    Primary Completion
    Apr 2012
    Completion
    Oct 2016
    NCT01294527
  • Not applicable
    Completed

    Safety and Performance of Electrodes Implanted in the Left Ventricle

    WiCS-LV system

    Heart Failure, Ventricular Dysfunction +3

    Enrollment
    39
    Start
    Jul 2013
    Primary Completion
    Aug 2015
    Completion
    Nov 2019
    NCT01905670
  • Observational
    Active, not recruiting

    WiCS-LV Post Market Surveillance Registry

    WiCS-LV System

    Cardiac Resynchronization Therapy

    Enrollment
    100
    Start
    Feb 2016
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2027est.
    NCT02610673
  • Not applicable
    Active, not recruiting

    Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

    WiSE System

    Heart Failure

    Enrollment
    300
    Start
    Jan 2018
    Primary Completion
    Nov 2027est.
    Completion
    Nov 2027est.
    NCT02922036
  • Not applicable
    Recruiting

    A Feasibility Study Implant of the WiSE® CRT System With an Intracardiac Pacemaker to Achieve Totally Leadless CRT

    WiSE CRT System

    Heart Failure

    Enrollment
    40
    Start
    Dec 2025
    Primary Completion
    Apr 2027est.
    Completion
    Apr 2027est.
    NCT06561932
  • Observational
    Recruiting

    The WiSE®-UP Study (The WiSE System Utilization & Performance Study)

    The Wise System

    Heart Failure

    Enrollment
    320
    Start
    Nov 2025
    Primary Completion
    Sep 2032est.
    Completion
    Sep 2032est.
    NCT07098858
Search ClinicalTrials.gov for “EBR Systems”